CoChat

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients

Open access
Nooka, Ajay K., Joseph, Nisha S., Kaufman, Jonathan L., Heffner, Leonard T., Gupta, Vikas A., Gleason, Charise, Boise, Lawrence H., Lonial, Sagar · 2019 · Cancer
Cited by 91

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background: The efficacy of daratumumab (DARA) both as a monotherapy and in combination with standard‐of‐care regimens in multiple myeloma (MM) has been established in clinical trials. This article presents a retrospective analysis of the safety and efficacy of DARA in combination with pomalidomide (POM) and dexamethasone (ie, daratumumab, pomalidomide, and dexamethasone [DARA‐POM‐D]) and, more importantly, the long‐term follow‐up of a cohort that was naive to DARA and POM as well as a cohort in which the utility of re‐treatment was evaluated among patients who were DARA‐ and/or POM‐refractory. Methods: Thirty‐four consecutive patients with relapsed and/or refractory MM treated with DARA‐POM‐D at the Winship Cancer Institute of Emory University from January 2015 through July 2016 were included in the analysis. The study was approved by Emory University's institutional review board. All received prior proteasome inhibitors and immunomodulatory drugs (IMiDs) and were refractory to their last line of therapy. Results: All patients were lenalidomide‐refractory, and 91% were bortezomib‐refractory. Two cohorts were identified on the basis of prior exposure to DARA and/or POM. Cohort 1 (12 patients) was DARA‐ and POM‐naive, and cohort 2 (22 patients) was DARA‐ and/or POM‐refractory. A subgroup of 12 patients in cohort 2 (cohort 3) was DARA‐ and POM‐refractory. The combination's tolerability was consistent with the results of the published phase 1b study (EQUULES) that evaluated the combination and no new safety signals were observed. The overall response rates (ORRs) were 91.7%, 40.9%, and 33.3% in cohorts 1, 2, and 3, respectively. Deep responses, including 4 stringent complete responses, were observed in cohort 1. In cohort 2, the ORR comprised 8 partial responses (PRs) and 1 very good PR. The median progression‐free survival (PFS) was not reached in cohort 1 at a median follow‐up of 41 months, and it was 3.2 months in cohort 2. DARA‐POM‐D not only was effective in DARA‐ and POM‐naive patients but also produced clinical responses in a third of patients re‐treated with these drugs. Conclusions: A better than quadrupled PFS benefit observed in cohort 1 in comparison with the previously reported benefit in the EQUULEUS trial (which led to US Food and Drug Administration approval of the DARA‐POM‐D combination) highlights the fact that the introduction of monoclonal antibody combination strategies and IMiDs as earlier lines of therapeutic options potentially could deliver better clinical outcomes. One‐third of patients refractory to separate lines of DARA and/or POM responded when they were re‐treated with a combination, and this resulted in survival benefits equivalent to those of other antimyeloma agents/combinations available for DARA‐refractory patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.32178

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 22

  1. 10.1038/bcj.2016.53 · DOI
  2. 10.1182/blood-2007-10-116129 · DOI · Paper page
  3. 10.1634/theoncologist.2016-0104 · DOI · Paper page
  4. 10.1111/bjh.12198 · DOI · Paper page
  5. 10.1182/asheducation-2005.1.220 · DOI
  6. 10.1038/leu.2009.236 · DOI · Paper page
  7. Raedler L, 2015, Velcade (bortezomib) receives 2 new FDA indications: for retreatment of patients with multiple myeloma and for first‐line treatment of patients with mantle‐cell lymphoma, Am Health Drug Benefits, 8, 135
  8. 10.1200/JCO.2016.69.5908 · DOI
  9. 10.1111/imr.12389 · DOI · Paper page
  10. 10.1182/blood-2015-12-687749 · DOI · Paper page
  11. 10.1056/NEJMoa1606038 · DOI · Paper page
  12. 2016, Darzalex™ (Daratumumab) Injection, for Intravenous Use [package insert]
  13. 10.1016/j.clml.2017.03.025 · doi:10.1016/j.clml.2017.03.025
  14. 10.1182/blood-2017-05-785246 · DOI · Paper page
  15. 10.1182/blood-2010-10-299487 · DOI · Paper page
  16. 10.1038/leu.2013.247 · DOI · Paper page
  17. 10.1016/j.clml.2017.02.018 · DOI
  18. Facon T, 2017, Daratumumab in combination with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma (RRMM) patients with ≥2 prior lines of therapy: updated analysis of MMY1001 [abstract], Blood, 130, 1824
  19. 10.1200/JCO.2018.36.15_suppl.TPS8059 · DOI
  20. 10.1111/bjh.13776 · DOI
  21. 10.1182/blood-2010-04-279893 · DOI · Paper page
  22. 10.1182/blood-2017-10-809293 · DOI · Paper page

Cited by

See all 91

Metadata

Authors
Nooka, A. K., Joseph, N. S., Kaufman, J. L., Heffner, L. T., Gupta, V. A., Gleason, C., Boise, L. H., & Lonial, S.
Venue
Cancer
Publisher
Wiley
Published
2019-05-15
Volume
125
Issue
17
Pages
2991-3000
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2945734108
Cited by
91
References
9
FWCI
8.61
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.